Logo image of 1MRNA.MI

MODERNA INC (1MRNA.MI) Stock Fundamental Analysis

BIT:1MRNA - Borsa Italiana Milan - US60770K1079 - Common Stock - Currency: EUR

33.98  -2.3 (-6.35%)

Fundamental Rating

3

1MRNA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 72 industry peers in the Biotechnology industry. The financial health of 1MRNA is average, but there are quite some concerns on its profitability. 1MRNA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year 1MRNA has reported negative net income.
1MRNA had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: 1MRNA reported negative net income in multiple years.
In multiple years 1MRNA reported negative operating cash flow during the last 5 years.
1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCF1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5B 10B

1.2 Ratios

With a decent Return On Assets value of -14.07%, 1MRNA is doing good in the industry, outperforming 65.63% of the companies in the same industry.
1MRNA has a Return On Equity of -18.65%. This is in the better half of the industry: 1MRNA outperforms 65.63% of its industry peers.
Industry RankSector Rank
ROA -14.07%
ROE -18.65%
ROIC N/A
ROA(3y)18.74%
ROA(5y)2.74%
ROE(3y)31.99%
ROE(5y)4.61%
ROIC(3y)N/A
ROIC(5y)N/A
1MRNA.MI Yearly ROA, ROE, ROIC1MRNA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60 80

1.3 Margins

1MRNA's Gross Margin of 78.43% is fine compared to the rest of the industry. 1MRNA outperforms 78.13% of its industry peers.
1MRNA's Gross Margin has declined in the last couple of years.
1MRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.72%
GM growth 5YN/A
1MRNA.MI Yearly Profit, Operating, Gross Margins1MRNA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

1MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
1MRNA has less shares outstanding than it did 1 year ago.
The number of shares outstanding for 1MRNA has been increased compared to 5 years ago.
Compared to 1 year ago, 1MRNA has an improved debt to assets ratio.
1MRNA.MI Yearly Shares Outstanding1MRNA.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M
1MRNA.MI Yearly Total Debt VS Total Assets1MRNA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B 20B 25B

2.2 Solvency

1MRNA has an Altman-Z score of 3.52. This indicates that 1MRNA is financially healthy and has little risk of bankruptcy at the moment.
1MRNA's Altman-Z score of 3.52 is fine compared to the rest of the industry. 1MRNA outperforms 79.69% of its industry peers.
1MRNA has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
1MRNA has a Debt to Equity ratio of 0.05. This is in the better half of the industry: 1MRNA outperforms 71.88% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 3.52
ROIC/WACCN/A
WACC10.65%
1MRNA.MI Yearly LT Debt VS Equity VS FCF1MRNA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5B 10B 15B

2.3 Liquidity

A Current Ratio of 4.39 indicates that 1MRNA has no problem at all paying its short term obligations.
The Current ratio of 1MRNA (4.39) is better than 73.44% of its industry peers.
1MRNA has a Quick Ratio of 4.20. This indicates that 1MRNA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.20, 1MRNA is doing good in the industry, outperforming 73.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.2
1MRNA.MI Yearly Current Assets VS Current Liabilites1MRNA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.75% over the past year.
1MRNA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -44.29%.
The Revenue has been growing by 119.30% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)37.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.31%
Revenue 1Y (TTM)-44.29%
Revenue growth 3Y104.31%
Revenue growth 5Y119.3%
Sales Q2Q%1.69%

3.2 Future

1MRNA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.78% yearly.
Based on estimates for the next years, 1MRNA will show a decrease in Revenue. The Revenue will decrease by -2.46% on average per year.
EPS Next Y24.44%
EPS Next 2Y12.32%
EPS Next 3Y12.96%
EPS Next 5Y12.78%
Revenue Next Year-50.04%
Revenue Next 2Y-35.01%
Revenue Next 3Y-20.01%
Revenue Next 5Y-2.46%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1MRNA.MI Yearly Revenue VS Estimates1MRNA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
1MRNA.MI Yearly EPS VS Estimates1MRNA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

1MRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 1MRNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1MRNA.MI Price Earnings VS Forward Price Earnings1MRNA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1MRNA.MI Per share data1MRNA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

1MRNA's earnings are expected to grow with 12.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.32%
EPS Next 3Y12.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 1MRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MODERNA INC

BIT:1MRNA (2/4/2025, 7:00:00 PM)

33.98

-2.3 (-6.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-14 2025-02-14/amc
Inst Owners72.76%
Inst Owner ChangeN/A
Ins Owners5.46%
Ins Owner ChangeN/A
Market Cap13.08B
Analysts66.67
Price Target68.19 (100.68%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.53%
Min EPS beat(2)3.51%
Max EPS beat(2)101.54%
EPS beat(4)4
Avg EPS beat(4)69.14%
Min EPS beat(4)3.51%
Max EPS beat(4)155.49%
EPS beat(8)6
Avg EPS beat(8)-1.23%
EPS beat(12)9
Avg EPS beat(12)4.31%
EPS beat(16)11
Avg EPS beat(16)-2.34%
Revenue beat(2)2
Avg Revenue beat(2)62.39%
Min Revenue beat(2)46.04%
Max Revenue beat(2)78.74%
Revenue beat(4)4
Avg Revenue beat(4)50.79%
Min Revenue beat(4)10.45%
Max Revenue beat(4)78.74%
Revenue beat(8)7
Avg Revenue beat(8)36.35%
Revenue beat(12)10
Avg Revenue beat(12)27.64%
Revenue beat(16)12
Avg Revenue beat(16)25.32%
PT rev (1m)-7.78%
PT rev (3m)-24.87%
EPS NQ rev (1m)1.52%
EPS NQ rev (3m)-864.91%
EPS NY rev (1m)1.01%
EPS NY rev (3m)0.57%
Revenue NQ rev (1m)-7.71%
Revenue NQ rev (3m)-57.57%
Revenue NY rev (1m)-1.28%
Revenue NY rev (3m)-0.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.66
P/FCF N/A
P/OCF N/A
P/B 1.13
P/tB 1.14
EV/EBITDA N/A
EPS(TTM)-5.63
EYN/A
EPS(NY)-8.87
Fwd EYN/A
FCF(TTM)-9.95
FCFYN/A
OCF(TTM)-8.06
OCFYN/A
SpS12.78
BVpS29.99
TBVpS29.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.07%
ROE -18.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.43%
FCFM N/A
ROA(3y)18.74%
ROA(5y)2.74%
ROE(3y)31.99%
ROE(5y)4.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.72%
GM growth 5YN/A
F-Score3
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 226.28%
Cap/Sales 14.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.2
Altman-Z 3.52
F-Score3
WACC10.65%
ROIC/WACCN/A
Cap/Depr(3y)117.07%
Cap/Depr(5y)134.11%
Cap/Sales(3y)4.65%
Cap/Sales(5y)15.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.31%
EPS Next Y24.44%
EPS Next 2Y12.32%
EPS Next 3Y12.96%
EPS Next 5Y12.78%
Revenue 1Y (TTM)-44.29%
Revenue growth 3Y104.31%
Revenue growth 5Y119.3%
Sales Q2Q%1.69%
Revenue Next Year-50.04%
Revenue Next 2Y-35.01%
Revenue Next 3Y-20.01%
Revenue Next 5Y-2.46%
EBIT growth 1Y19.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.26%
EBIT Next 3Y13.59%
EBIT Next 5Y15.36%
FCF growth 1Y-163.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-148.38%
OCF growth 3YN/A
OCF growth 5YN/A